Substituted heterocycle fused gamma-carbolines

• US 7,238,690 B2
• Filed: 03/15/2006
• Issued: 07/03/2007
• Est. Priority Date: 06/15/1999
• Status: Expired due to Term

• Current Assignee: Bristol-Myers Squibb Pharma Company (Bristol-Myers Squibb Company)
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: Mitchell, Ian S., Deng, Wei, Lee, Taekyu, Robichaud, Albert J., Chen, Wenting, McClung, Christopher D., Zawrotny, David M., Calvello, Emilie J.
• Primary Examiner(s): Kifle; Bruck
• Application Number:
  US11/375,935
• Publication Number:
  US 20060178362A1
• Time in Patent Office: 475 Days
• Field of Search: 544/99, 514/229.5
• US Class Current: 514/229.5
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 221/18 Ring systems of four or more rings
• CPC Class Codes: C07D 223/32 containing carbocyclic rings other than six-membered
• CPC Class Codes: C07D 471/06 Peri-condensed systems
• CPC Class Codes: C07D 491/06 Peri-condensed systems
• CPC Class Codes: C07D 495/06 Peri-condensed systems

Abstract

The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I)

or pharmaceutically acceptable salt forms thereof, wherein R¹, R⁵, R^6a, R^6b, R⁷, R⁸, R⁹, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

Claims

1. A compound or a pharmaceutically acceptable salt form thereof according to the following formula:

3. A pharmaceutical composition, comprising:

the compound according to claim 1; and

at least one pharmaceutically acceptable carrier or diluent.

2. A compound or a pharmaceutically acceptable salt form thereof according to the following formula:

4. A pharmaceutical composition, comprising:

the compound according to claim 2; and

at least one pharmaceutically acceptable carrier or diluent.